...

 
Cannvas.Me
Sign Up For Free
Scythian Biosciences Corp. and its partners at the University of Miami Miller School of Medicine announced the results of a pre-clinical study evaluating the safety and efficacy of a cannabis derived combination therapy in treating mild to moderate traumatic brain injury (TBI) in rodents. 

In the study, researchers treated rodents with a cannabinoid derived combination of CBD and HU211, and compared it to the results of treating the rodents with the two substances alone. Those treated with the combination of the two experienced a greater improvement, and no adverse effects, compared to be treating with the substances alone. 

To read the full press release, follow the link below.
https://globenewswire.com/news-release/2018/07/13/1537285/0/en/Scythian-Biosciences-Announces-Positive-Pre-Clinical-Data-on-the-Safety-and-Efficacy-of-Cannabis-Derived-Combination-Therapy-for-Mild-to-Moderate-Traumatic-Brain-Injury.html

This article is now marked as read.

Was this article helpful?

Review this article to help us continue creating and sharing relevant content.

Please note it may take up to two business days for reviews to be validated and published.

Reviews

Review this article to help us continue creating and sharing relevant content.

Write Review

Would you like to
make this review public?

Please disable your ad blocker to avoid issues using social plugins on Cannvas.Me. Thanks.
Close